Company / PP&E (Net)
Myriad Genetics, Inc. PP&E (Net) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$114.0M
FY2025
5-year range
$43.5M / $119.0M
FY2021-FY2025
Trend
-2.9%
vs FY2024
Sector context
#42 of 193
Health Care
What the data says
Myriad Genetics, Inc.'s pp&e (net) of $114M is higher than 78% of companies in the Health Care sector (FY2025). PP&E (Net) has fluctuated over the past 10 years, ranging from $41M in FY2020 to $119M in FY2023.
Based on SEC 10-K filings.
$114M in FY2025 with a 5-year CAGR of +22.9%. Top quartile in the Health Care sector.
Declined from $119M to $114M over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- +11.0%
- 5-Year CAGR
- +22.9%
- 10-Year CAGR
- -
Sector benchmark
Top 22% in Health CareTop 22% of 193This company $114.0M Sector average $777.6M
▼
-85.3% below sector average
Key checks
Key Insights
- 5-year CAGR of +22.9%, indicating consistent growth.
- In FY2025, pp&e (net) decreased 2.9% year-over-year.
- Ranks #42 out of 193 companies in the Health Care sector.
- Peak pp&e (net) was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score -1.23 (distress zone, below 1.8 threshold)
- Negative profit margin: -15.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $114.0M | -2.9% |
| FY2024 | $117.4M | -1.3% |
| FY2023 | $119.0M | +42.7% |
| FY2022 | $83.4M | +91.7% |
| FY2021 | $43.5M | +6.9% |
| FY2020 | $40.7M | -29.0% |
| FY2019 | $57.3M | +32.6% |
| FY2018 | $43.2M | -15.5% |
| FY2017 | $51.1M | -12.3% |
| FY2016 | $58.3M | -13.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026